Option Care Health Announces Financial Results for The Second Quarter Ended June 30, 2024
Second Quarter 2024 Financial Results and Highlights
- Net revenue of
$1,227.2 million , up 14.8% compared to$1,069.1 million in the second quarter of 2023 - Gross profit of
$249.4 million , or 20.3% of net revenue, down 0.6% compared to$250.8 million , or 23.5% of net revenue, in the second quarter of 2023 - Net income of
$53.0 million , or$0.30 diluted earnings per share, down 53.6% compared to net income of$114.4 million , or$0.63 diluted earnings per share, in the second quarter of 2023 - Adjusted EBITDA of
$108.4 million , down 1.5% compared to$110.1 million in the second quarter of 2023 - Cash flow from operations of
$195.7 million , compared to$169.5 million in the second quarter of 2023 - Cash and cash equivalents balance of
$376.9 million at the end of the second quarter of 2024 - Repurchased approximately
$78.1 million of stock - Amended the First Lien Credit Agreement reducing the interest rate to Term SOFR plus 2.25% and providing
$50 .0 million of additional liquidity
Note that the second quarter of 2023 net income and cash flow from operations includes
Updated Full Year 2024 Financial Guidance
For the full year 2024,
- Net revenue of
$4 .75 billion to$4 .85 billion - Adjusted EBITDA of $435 million to $450 million
- Cash flow from operations of at least $300 million, consistent with previous guidance
- Effective tax rate of 26% - 28%, consistent with previous guidance
- Net interest expense of approximately $55 million to $60 million, consistent with previous guidance
Conference Call
About
Investor Contacts
Chief Financial Officer | Westwicke |
T: (312) 940-2538 | T: (413) 213-0500 |
mike.shapiro@optioncare.com | optioncarehealth@westwicke.com |
Forward-Looking Statements - Safe Harbor
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: changes in laws and regulations applicable to our business model; changes in market conditions and receptivity to our services and offerings; pending and future litigation; potential liability for claims not covered by insurance; and loss of relationships with managed care organizations and other non-governmental third party payers. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Note Regarding Use of Non-GAAP Financial Measures
In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company’s liquidity. In addition, the Company's definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other. As part of restructuring, acquisition, integration and other, the Company may incur significant charges such as the write down of certain long‑lived assets, temporary redundant expenses, professional fees, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information regarding the performance of Option Care Health’s business operations and facilitates comparisons to the Company’s historical operating results. We have not reconciled Adjusted EBITDA guidance to net income as management believes creation of this reconciliation would not be practicable due to the uncertainty regarding, and potential variability of, material reconciling items. For a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see below.
Schedule 1 |
CONDENSED CONSOLIDATED BALANCE SHEETS |
(IN THOUSANDS)(UNAUDITED) |
ASSETS | |||||
CURRENT ASSETS: | |||||
Cash and cash equivalents | $ | 376,872 | $ | 343,849 | |
Accounts receivable, net | 468,300 | 377,658 | |||
Inventories | 281,421 | 274,004 | |||
Prepaid expenses and other current assets | 100,820 | 98,744 | |||
Total current assets | 1,227,413 | 1,094,255 | |||
NONCURRENT ASSETS: | |||||
Property and equipment, net | 123,931 | 120,630 | |||
Intangible assets, net | 18,542 | 20,092 | |||
Referral sources, net | 299,660 | 315,304 | |||
1,540,246 | 1,540,246 | ||||
Other noncurrent assets | 138,800 | 126,508 | |||
Total noncurrent assets | 2,121,179 | 2,122,780 | |||
TOTAL ASSETS | $ | 3,348,592 | $ | 3,217,035 | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||
CURRENT LIABILITIES: | |||||
Accounts payable | $ | 535,688 | $ | 426,513 | |
Other current liabilities | 159,719 | 191,796 | |||
Total current liabilities | 695,407 | 618,309 | |||
NONCURRENT LIABILITIES: | |||||
Long-term debt, net of discount, deferred financing costs and current portion | 1,105,575 | 1,056,650 | |||
Other noncurrent liabilities | 136,179 | 120,404 | |||
Total noncurrent liabilities | 1,241,754 | 1,177,054 | |||
Total liabilities | 1,937,161 | 1,795,363 | |||
STOCKHOLDERS’ EQUITY | 1,411,431 | 1,421,672 | |||
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 3,348,592 | $ | 3,217,035 | |
Schedule 2 |
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS |
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED) |
Three Months Ended |
Six Months Ended |
||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||
NET REVENUE | $ | 1,227,186 | $ | 1,069,072 | $ | 2,373,238 | $ | 2,084,920 | |||||||
COST OF REVENUE | 977,821 | 818,243 | 1,885,373 | 1,605,086 | |||||||||||
GROSS PROFIT | 249,365 | 250,829 | 487,865 | 479,834 | |||||||||||
OPERATING COSTS AND EXPENSES: | |||||||||||||||
Selling, general and administrative expenses | 153,783 | 153,564 | 308,525 | 301,430 | |||||||||||
Depreciation and amortization expense | 14,907 | 14,898 | 29,635 | 29,412 | |||||||||||
Total operating expenses | 168,690 | 168,462 | 338,160 | 330,842 | |||||||||||
OPERATING INCOME | 80,675 | 82,367 | 149,705 | 148,992 | |||||||||||
OTHER INCOME (EXPENSE): | |||||||||||||||
Interest expense, net | (12,603 | ) | (13,196 | ) | (25,805 | ) | (27,030 | ) | |||||||
Other, net | 3,969 | 86,332 | 5,096 | 87,770 | |||||||||||
Total other (expense) income | (8,634 | ) | 73,136 | (20,709 | ) | 60,740 | |||||||||
INCOME BEFORE INCOME TAXES | 72,041 | 155,503 | 128,996 | 209,732 | |||||||||||
INCOME TAX EXPENSE | 18,998 | 41,100 | 31,162 | 56,121 | |||||||||||
NET INCOME | $ | 53,043 | $ | 114,403 | $ | 97,834 | $ | 153,611 | |||||||
Earnings per share, basic | $ | 0.31 | $ | 0.64 | $ | 0.56 | $ | 0.85 | |||||||
Earnings per share, diluted | $ | 0.30 | $ | 0.63 | $ | 0.56 | $ | 0.84 | |||||||
Weighted average common shares outstanding, basic | 172,927 | 179,807 | 173,428 | 180,531 | |||||||||||
Weighted average common shares outstanding, diluted | 174,090 | 181,241 | 174,831 | 181,931 | |||||||||||
Schedule 3 |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
(IN THOUSANDS)(UNAUDITED) |
Six Months Ended |
|||||||
2024 | 2023 | ||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||
Net income | $ | 97,834 | $ | 153,611 | |||
Adjustments to reconcile net income to net cash provided by operations: | |||||||
Depreciation and amortization expense | 30,802 | 30,801 | |||||
Other non-cash adjustments | 38,874 | 38,498 | |||||
Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | (90,642 | ) | (18,619 | ) | |||
Inventories | (7,417 | ) | (38,643 | ) | |||
Accounts payable | 107,558 | 88,896 | |||||
Accrued compensation and employee benefits | (30,206 | ) | (3,949 | ) | |||
Prepaid expenses and other current assets | (1,745 | ) | 654 | ||||
Other | (18,187 | ) | 8,039 | ||||
Net cash provided by operating activities | 126,871 | 259,288 | |||||
CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||
Acquisition of property and equipment | (15,597 | ) | (13,554 | ) | |||
Business acquisitions, net of cash acquired | — | (12,855 | ) | ||||
Net cash used in investing activities | (15,597 | ) | (26,409 | ) | |||
CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||
Purchase of company stock | (118,122 | ) | (75,000 | ) | |||
Proceeds from issuance of debt | 49,959 | — | |||||
Other financing cash flows | (10,088 | ) | (10,899 | ) | |||
Net cash used in financing activities | (78,251 | ) | (85,899 | ) | |||
NET INCREASE IN CASH AND CASH EQUIVALENTS | 33,023 | 146,980 | |||||
Cash and cash equivalents - beginning of the period | 343,849 | 294,186 | |||||
CASH AND CASH EQUIVALENTS - END OF PERIOD | $ | 376,872 | $ | 441,166 | |||
Schedule 4 |
QUARTERLY RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES |
(IN THOUSANDS)(UNAUDITED) |
Three Months Ended |
Six Months Ended |
||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||
Net income | $ | 53,043 | $ | 114,403 | $ | 97,834 | $ | 153,611 | |||||
Interest expense, net | 12,603 | 13,196 | 25,805 | 27,030 | |||||||||
Income tax expense | 18,998 | 41,100 | 31,162 | 56,121 | |||||||||
Depreciation and amortization expense | 15,497 | 15,576 | 30,802 | 30,801 | |||||||||
EBITDA | 100,141 | 184,275 | 185,603 | 267,563 | |||||||||
EBITDA adjustments | |||||||||||||
Stock-based incentive compensation | 7,608 | 7,685 | 17,213 | 13,673 | |||||||||
Loss on extinguishment of debt | 377 | — | 377 | — | |||||||||
Restructuring, acquisition, integration and other (1) | 231 | (81,910 | ) | 3,454 | (77,412 | ) | |||||||
Adjusted EBITDA | $ | 108,357 | $ | 110,050 | $ | 206,647 | $ | 203,824 |
(1) Restructuring, acquisition, integration and other for the three and six months ended
![](https://ml.globenewswire.com/media/YzMwMjNhNDQtYmM3NC00MWRjLTllODctMjk4YWM2NGYzMjQwLTExOTUzNTI=/tiny/Option-Care-Enterprises-Inc-.png)
Source: Option Care Health, Inc.